A Relative Bioavailability Study of Selpercatinib (LY3527723) in Healthy Participants

Authors
Category Primary study
Registry of Trialsclinicaltrials.gov
Year 2021
The main purpose of this study is to compare the amount of selpercatinib that gets into the blood stream and how long it takes the body to get rid of it, when given as three different formulations in adult healthy participants. The information about any adverse effects experienced will be collected and the tolerability of selpercatinib will also be evaluated. The study may last up to 59 days including the 28 days of screening period.
Epistemonikos ID: b7ccf8c8b200f0da2c0030b8be45718093915f89
First added on: May 09, 2024